Navigation Links
Early Drug Treatment May Cut Multiple Sclerosis Risk
Date:10/6/2009

Improved rates of prevention or delay of full-blown disease seen in treated study patients

TUESDAY, Oct. 6 (HealthDay News) -- Among patients who show early signs of multiple sclerosis, treatment with a drug called glatiramer acetate appears to halve the risk that they will develop full-blown disease, new research suggests.

About 85 percent of patients who are diagnosed with multiple sclerosis first show signs of a "clinical event" that goes away. But many people who have this happen -- about one-third -- don't go on to develop the disease, and most of the rest won't be severely disabled, research has shown.

In the new study, published in Oct. 6 online edition of The Lancet, 481 people who showed possible signs of multiple sclerosis were assigned to receive either a placebo or glatiramer acetate for up to 36 months. The dosage for those who received the active drug was 20 milligrams per day.

The researchers found that glatiramer acetate reduced the risk of developing the disease by 45 percent compared to the placebo, and it took longer for some patients to develop the disease -- it was an average of about two years for those who took the drug compared to about one year for those who didn't.

Injection-related side effects were common: more than half of those who were given glatiramer acetate developed problems around the site of their injections, and about 19 percent had reactions right after receiving the treatment. By comparison, 24 percent of those who were given the placebo had reactions at the site of their injections, and only 5 percent had problems immediately after the treatment, according to the study authors.

"This study establishes glatiramer acetate as an option for patients with clinically isolated syndrome who choose to start treatment early to improve control of the underlying disease process," the researchers concluded.

More information

Learn more about multiple sclerosis from the National Multiple Sclerosis Society.



-- Randy Dotinga



SOURCE: The Lancet, news release, Oct. 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Early H1N1 Vaccination Saves Lives, Cuts Costs: Study
2. New Government Research Finds One in Every 100 Children Has Autism, of Whom Nearly 40% Are Recovered
3. Molecular imaging holds promise for early intervention in common uterine cancer
4. A potential new imaging agent for early diagnosis of most serious skin cancer
5. Clearly Contacts Director of Web Sales Named as One of Canada's Top Online Marketers of 2009
6. Training clinicians helps reduce rates of early childhood cavities
7. Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women
8. Analysis Shows Narrow Age Rating Would Raise Premiums by Nearly 50 Percent, Causing Many Young and Healthy to Forgo Coverage
9. Switching early breast cancer patients to exemestane improves long-term survival
10. LA County Announces: Nearly 40,000 Seniors and Disabled to Lose Home Care Service Hours Due to State Budget Cuts
11. New device finds early signs of eye disease in preemies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology: